President & CEO
Taiho Oncology, Inc.
Timothy Whitten joined Taiho Oncology in 2013 as the Senior Vice President and CCO to build the first commercial business unit for Taiho in the West and to oversee the company’s commercial functions. In 2017, Mr. Whitten was promoted to Senior Vice President and COO, adding human resources and operations of Taiho Pharma Canada, Inc. to his responsibilities. On January 1, 2018, Mr. Whitten was promoted to President, Taiho Oncology, Inc., and given a position on the Taiho Oncology Board of Directors as he assumed leadership responsibility for corporate, commercial and clinical development-related functions at Taiho Oncology. In addition, Mr. Whitten serves as President of Taiho Pharma Canada and holds a seat on the Taiho Pharma Canada Board, as well as having operational responsibility for Taiho Pharma Europe, Ltd. As of April 1, 2018, Mr. Whitten has been named President and CEO of Taiho Oncology, reporting directly to Masayuki Kobayashi, President and Representative Director Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, following Eric Benn’s retirement as CEO, Taiho Oncology, Inc. Prior to joining Taiho Oncology, Inc., Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time, he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, Mr. Whitten took the private company, Transave, into the public marketplace via a business combination with lnsmed. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of Taxol® into the U.S. oncology market. Mr. Whitten graduated from West Virginia University with a Bachelor of Science in Pharmacy and from the University of Virginia with a Master of Business Administration.